News about Global Pharma

Antag Therapeutics Gets FDA Clearance IND Application for AT-7687

The study will also explore AT-7687 as a monotherapy and in combination with semaglutide, a GLP-1 receptor agonist, in healthy obese individuals.

Global Pharma | 09/10/2024 | By Aishwarya |  644

Seegene and Werfen Finalize Collaboration Deal on Technology-Sharing Initiative

Under the agreement, Seegene and Werfen will set up a NewCo in Spain, Werfen-Seegene, upon the conclusion of mandatory government approvals anticipated by the first half of 2025.

Global Pharma | 09/10/2024 | By Aishwarya |  582

Exothera Welcomes Cedric Volanti as New CEO

Cédric Volanti brings a wealth of experience and a strong strategic vision.

Global Pharma | 09/10/2024 | By Aishwarya |  542

Innovent Partners with Ask Pharm for Limertinib for Treatment of Lung Cancer

Under the agreement, Innovent will obtain the exclusive commercialization rights for limertinib in mainland China, and will be entitled to receive a commercialization service fee based on the product's net sales in the region.

Global Pharma | 08/10/2024 | By Aishwarya |  638

OneSource Unveils New Brand Identity at CPHI Milan

OneSource’s end-to-end offering across all its platforms was established in response to its customers’ need to streamline supply chains by consolidating their outsourcing partners.

Global Pharma | 08/10/2024 | By Aishwarya |  1082

ABL Bio Signs Clinical Alliance with MSD to Evaluate ABL103 with KEYTRUDA

Under the terms of the agreement, ABL Bio will conduct a phase 1b/2 clinical trial to evaluate the safety and efficacy of ABL103 in combination with KEYTRUDA. In this combination study, MSD will supply KEYTRUDA.

Global Pharma | 07/10/2024 | By Aishwarya |  744

Synexa Life Sciences Acquires CRO Alderley Analytical

Alderley Analytical’s services complement Synexa Life Sciences’ established capabilities in biomarker and bioanalytical assays—covering DNA, RNA, protein, cell, and tissue analysis.

Global Pharma | 07/10/2024 | By Aishwarya |  354

Alembic Pharma Gets FDA Approval for Lamotrigine Extended-Release Tablets

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lamictal XR Extended-Release Tablets, 200 mg, 250 mg, and 300 mg, of GlaxoSmithKline LLC (GSK).

Global Pharma | 07/10/2024 | By Aishwarya |  750

MD Logistics to Launch Dedicated Pharmaceutical Warehouse in Indiana

The warehouse undergoing renovations is the largest in MD's network at approximately 37,000 m2.

Global Pharma | 07/10/2024 | By Aishwarya |  838

Johnson & Johnson Submits sBLA to FDA for Approval of DARZALEX FASPRO-Based Quadruplet Regimen

The CEPHEUS study evaluated the efficacy and safety of D-VRd compared to bortezomib, lenalidomide and dexamethasone (VRd) for NDMM patients for whom ASCT was not planned as initial therapy.

Global Pharma | 01/10/2024 | By Aishwarya |  319